During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Stephanie L. Graff, MD (Moderator)
Director of Breast Oncology
Lifespan Cancer Institute
Providence, RI
CASE SUMMARY
Medical/Social History
Initial Diagnostic and Surgical Procedures
Three Years After Completing Letrozole
Follow-Up Diagnostic Tests
First-Line Therapy: CDK4/6 Inhibitor + Aromatase Inhibitor
DISCUSSION QUESTIONS
STEPHANIE L. GRAFF, MD: How are you sequencing ADCs in your treatment of advanced or metastatic HR-positive HER2 0 breast cancer? When are you considering it in second line vs third line? If this patient were HER2 low, how are you considering it and comparing it to T-DXd?
ANKUR MEHTA, MD: About [if the patient had] HER2-low disease, I would choose T-DXd before sacituzumab. In terms of the HER2 0 after the second biopsy, the algorithm would be either capecitabine prior to going on to sacituzumab. In the event the patient has not seen any prior chemotherapy or taxanes in the adjuvant setting and if they don't have any issues, then I have sometimes used eribulin [Halaven] ahead, depending on the volume of disease.
ERIN DAUCHY, DO: Granted, I am still fairly new in my practice, but a lot of times in the early metastatic setting, my patients are still eager to stay on oral therapy for as long as they can. Usually I'll do capecitabine first and at least the patients who did not have de novo metastatic disease usually had seen a taxane and some of them still have neuropathy, so I try to save those for later on. What I've seen so far in my practice is eventually a lot of these ER-positive patients develop visceral compromise, and I have the taxane in my back pocket for that.
BARBARA S. CIVIELLO, MD: I agree with what people have said so far. I think with individual patients, it tends to be a discussion point. I would use T-DXd before sacituzumab. Also for sequencing, if I wasn't worried about significant risk of pneumonitis in a patient, I would use it before sacituzumab. With the payloads being similar, there's still the question of can you use them one after another? It's a discussion with oral therapies; people don't typically want to be in clinic very long. I have more fatigue with my patients receiving sacituzumab than I do with my patients receiving T-DXd, so I think it's a discussion among many good options.
GRAFF: I'm surprised that you don't have as much fatigue; I feel like fatigue is my number one T-DXd adverse event.
CIVIELLO: I don't know why. I was fearful of pneumonitis, but I have quite a number of patients on T-DXd and they're tolerating it well, and I know that there is fatigue listed as an adverse event, but it just has not been what my patients are experiencing.
MARK SHPARBER, MD: If your patient has never seen doxorubicin [Adriamycin], it's a wonderful drug. It works very well in HR-positive patients. I know we have these million-dollar drugs and they're all very fancy, but an old-fashioned drug like doxorubicin works very well if the patient has not seen it in the past.
GRAFF: I completely agree. I am not afraid to give doxorubicin in HR-positive breast cancer. I'm surprised how often that is the recommendation that patients have when they come to me for second opinions, because I feel like a lot of the times when I see a second opinion, I'm seeing them in [very late stages, like the] eighth line, and that's the drug they haven't had yet. It boggles my mind every time.
Genetics and Ring Sideroblasts Impact ESA-Refractory Anemia in MDS
September 5th 2024During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.
Read More
Lower-Intensity Talquetamab Dose Shows Potential in Multiple Myeloma
August 30th 2024During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed the MonumenTAL-1 trial of talquetamab in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Nivolumab Combinations Debated for a Patient With Metastatic Melanoma
August 28th 2024During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants considered nivolumab/ipilimumab and nivolumab/relatlimab as options for a patient with metastatic melanoma in the first article of a 2-part series.
Read More
Participants Consider the Necessity of Chemo in HER2+ Breast Cancer
August 22nd 2024During a Case-Based Roundtable® event, Ian Krop, MD, PhD, discussed the use of chemotherapy in patients with HER2- and hormone receptor–positive metastatic breast cancer in combination with trastuzumab.
Read More